Scientists are currently working on the production of a new medication for Alzheimers. If tests are considered successful (these will be carried out later this year) then the drug called, Intepirdine, will be the first new treatment for Alzheimers in over a decade.
Alzheimers is the most common cause of dementia, but not the only one. Symptomology will really depend on the parts of the brain that have been damaged as a result of the disease which has caused it. Most common symptoms are: difficulty in concentrating, planning and/or organising; a memory loss, and difficulty in orientating etc.
Makers of Intepirdine have revealed that it intends to decrease the chemical in Alzheimer patient’s brains that plays a crucial role in the individual’s memory function.
Developers of Intepirdine acknowledge the fact that there has been an extensive number of experimental treatments in the past failing in the early stages of clinical trials. However, Intepirdine is considered to be different to previous attempts to develop a new drug to treat Alzheimers as Intepirdine has been proved to work in tandem with already existing medication that is there to help individuals with dementia to live independently for a considerably longer period of time.
Lawrence Friedhoff of Axovant (a company who is producing Intepirdine) has said:- “Studies based on theory can be successful, but several hundred of them have failed. Our trial is replicating a study that already shows statistically significant benefit to humans, so it has a much higher chance of being successful.”
The last drug that was approved was Donepezil in 2002, some 15 years ago, and therefore, whilst Intepirdine is not guaranteed to succeed, for now it is considered to be the only new plausible treatment.
Currently around 1,150 patients with mild to moderate Alzheimers are taking part in the international trial which was offered to them in clinics all around the UK. The trial is to finish this Autumn and if it will be considered successful, Intepirdine will be submitted for approval.
David Reynolds, Chief Scientific Officer at Alzheimer`s Research UK has said: “Until we have the data I can't comment as to whether this is a fantastic new treatment for patients to improve their symptoms, or whether in a few months’ time it will join the unfortunately long list of compounds that haven't worked.”
Let`s be hopeful that Intepirdine will be successful in treating Alzheimer`s.
The Clinical Negligence team at Swain & Co Solicitors regularly win compensation for their clients who have experienced substandard treatment or a failure to provide treatment. If you, a family member or a friend have experienced problems regarding substandard medical treatment contact our team today on 0292 483 322.